• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Early intervention with daratumumab improves survival for patients with high-risk smouldering myeloma.

作者信息

Nadeem Omar, Ghobrial Irene M

机构信息

Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

出版信息

Nat Rev Clin Oncol. 2025 Mar;22(3):159-160. doi: 10.1038/s41571-025-00987-2.

DOI:10.1038/s41571-025-00987-2
PMID:39856237
Abstract
摘要

相似文献

1
Early intervention with daratumumab improves survival for patients with high-risk smouldering myeloma.早期使用达雷妥尤单抗进行干预可提高高危冒烟型骨髓瘤患者的生存率。
Nat Rev Clin Oncol. 2025 Mar;22(3):159-160. doi: 10.1038/s41571-025-00987-2.
2
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.来那度胺联合地塞米松与观察治疗高危冒烟型多发性骨髓瘤患者（QuiRedex）：一项随机、对照、3 期临床试验的长期随访。
Lancet Oncol. 2016 Aug;17(8):1127-1136. doi: 10.1016/S1470-2045(16)30124-3. Epub 2016 Jul 9.
3
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.达雷妥尤单抗改善不适合移植的高危初诊多发性骨髓瘤患者的缓解深度和无进展生存期。
Oncologist. 2022 Jul 5;27(7):e589-e596. doi: 10.1093/oncolo/oyac067.
4
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.达雷妥尤单抗或高危冒烟型多发性骨髓瘤的主动监测
N Engl J Med. 2025 May 8;392(18):1777-1788. doi: 10.1056/NEJMoa2409029. Epub 2024 Dec 9.
5
Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratumumab efficacy .表征骨髓瘤患者单次运动如何影响血液中克隆性浆细胞和免疫效应细胞频率以及达雷妥尤单抗的疗效。
Brain Behav Immun Health. 2024 Sep 19;42:100865. doi: 10.1016/j.bbih.2024.100865. eCollection 2024 Dec.
6
Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.达雷妥尤单抗单药治疗与泊马度胺联合低剂量地塞米松治疗多发性骨髓瘤的疗效比较：匹配调整间接比较。
Oncologist. 2018 Mar;23(3):279-287. doi: 10.1634/theoncologist.2017-0103. Epub 2017 Nov 30.
7
Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.伴意义未明单克隆丙种球蛋白血症或冒烟型多发性骨髓瘤患者的个体化进展预测（PANGEA）：一项回顾性、多队列研究。
Lancet Haematol. 2023 Mar;10(3):e203-e212. doi: 10.1016/S2352-3026(22)00386-6.
8
Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study.轻链冒烟型多发性骨髓瘤（特发性本斯·琼斯蛋白尿）的临床病程：一项回顾性队列研究
Lancet Haematol. 2014 Oct 1;1(1):e28-e36. doi: 10.1016/S2352-3026(14)70001-8.
9
Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma: A network meta-analysis.达雷妥尤单抗联合标准治疗方案用于初诊多发性骨髓瘤患者：一项网状 Meta 分析。
Eur J Haematol. 2019 Dec;103(6):542-551. doi: 10.1111/ejh.13317. Epub 2019 Oct 1.
10
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.达雷妥尤单抗、来那度胺和地塞米松与来那度胺和地塞米松单独治疗新诊断多发性骨髓瘤（MAIA）的疗效比较：一项随机、开放标签、3 期临床试验的总生存结果。
Lancet Oncol. 2021 Nov;22(11):1582-1596. doi: 10.1016/S1470-2045(21)00466-6. Epub 2021 Oct 13.

本文引用的文献

1
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.达雷妥尤单抗或高危冒烟型多发性骨髓瘤的主动监测
N Engl J Med. 2025 May 8;392(18):1777-1788. doi: 10.1056/NEJMoa2409029. Epub 2024 Dec 9.
2
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma.会前圆桌讨论：前期多发性骨髓瘤的最优临床试验设计。
Blood Cancer Discov. 2024 May 1;5(3):146-152. doi: 10.1158/2643-3230.BCD-24-0022.
3
Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.
伴意义未明单克隆丙种球蛋白血症或冒烟型多发性骨髓瘤患者的个体化进展预测（PANGEA）：一项回顾性、多队列研究。
Lancet Haematol. 2023 Mar;10(3):e203-e212. doi: 10.1016/S2352-3026(22)00386-6.
4
MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology.MinimuMM-seq：用于多发性骨髓瘤病理微创分子特征分析的循环肿瘤细胞基因组测序
Cancer Discov. 2023 Feb 6;13(2):348-363. doi: 10.1158/2159-8290.CD-22-0482.
5
Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study.来那度胺-地塞米松对比观察在中位随访时间 12 年后高危冒烟型骨髓瘤中的疗效：一项随机、开放标签研究。
Eur J Cancer. 2022 Oct;174:243-250. doi: 10.1016/j.ejca.2022.07.030. Epub 2022 Sep 5.
6
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).国际骨髓瘤工作组冒烟型多发性骨髓瘤（SMM）的风险分层模型。
Blood Cancer J. 2020 Oct 16;10(10):102. doi: 10.1038/s41408-020-00366-3.
7
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.随机 Lenalidomide 对照观察冒烟型多发性骨髓瘤。
J Clin Oncol. 2020 Apr 10;38(11):1126-1137. doi: 10.1200/JCO.19.01740. Epub 2019 Oct 25.
8
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.纳入修订后 IMWG 诊断标准的冒烟型多发性骨髓瘤的风险分层。
Blood Cancer J. 2018 Jun 12;8(6):59. doi: 10.1038/s41408-018-0077-4.